MedTrace Logo

TNF-alpha Inhibition in CRPS: A Randomized Controlled Trial

NCT02031211 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2016-10-14

No results posted yet for this study

Summary

Studying the effects of Etanercept (an anti-Tumor Necrosis Factor alpha) on early Chronic Regional Pain Syndrome (CRPS). Our hypothesis is that Etanercept will improve patient symptoms if given in early CRPS.

Conditions

  • CRPS
  • Chronic Regional Pain Syndrome

Interventions

DRUG

Etanercept

The patient will receive 0.4 ml/kg as the 25mg/ml preparation subcutaneously.

DRUG

Placebo

The patient will receive 0.4 ml/kg of Normal Saline injected subcutaneously.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
10 Years
Max Age
17 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2016-10-31
Completion
2016-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02031211 on ClinicalTrials.gov